Imagen de Portada
Código QR

Arixtra: four weeks of Tx significantly reduces DVT/PE risk in hip fracture patients.

Publicado en:Formulary Vol. 37; no. 10; pp. 505 - 506
Formato: brief item Journal Article
Publicado: MJH Life Sciences Oct2002
Acceso en línea:Ver este registro en EBSCOhost
fields @attributes:
  recordID: 1
pdfLink:
plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=105529980&site=ehost-live
header:
  @attributes:
    shortDbName: ccm
    uiTerm: 105529980
    longDbName: CINAHL Complete
    uiTag: AN
  controlInfo:
    bkinfo:
    dissinfo:
    jinfo:
      jid:
        1082801X
        FRM
      jtl: Formulary
      issn: 1082801X
      maglogo: N
    pubinfo:
      dt: Oct2002
      vid: 37
      iid: 10
      pid: 54670
      pub: MJH Life Sciences
      place: Cranbury, New Jersey
    artinfo:
      ui:
        105529980
        105529980
        2010267561
        105529980
      ppf: 505
      ppct: 1
      formats:
      tig:
        atl: Arixtra: four weeks of Tx significantly reduces DVT/PE risk in hip fracture patients.
      aug:
      sug:
        subj:
          Anticoagulants Therapeutic Use
          Pulmonary Embolism Prevention and Control
          Venous Thromboembolism Drug Therapy
          Venous Thrombosis Prevention and Control
      pubtype: Academic Journal
      doctype:
        brief item
        Journal Article
      ougenre: Article
      ab:
    language: English
    refInfo:
    holdings:
      @attributes:
        islocal: N